At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADIL Adial Pharmaceuticals
Post-Mkt 12-05 18:17:13 EST
0.3086
-0.0176
-5.40%
盘后0.3189
+0.0103+3.34%
18:12 EST
High0.3219Low0.3038Vol231.24K
Open0.3170D1 Closing0.3262Amplitude5.55%
Mkt Cap7.40MTradable Cap7.37MTotal Shares23.99M
T/O71.91KT/O Rate0.97%Tradable Shares23.88M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Adial Pharmaceuticals announces $2.86M warrant inducement transaction
TIPRANKS  ·  11-26
Adial Pharmaceuticals announces $2.86M warrant inducement transaction
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
GlobeNewswire  ·  11-26
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating
TIPRANKS  ·  11-19
Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  11-17
Calendar of U.S. Earnings Expected in the Week Ahead
Adial Pharmaceuticals reports Q3 net loss of $1.8 million
Reuters  ·  11-14
Adial Pharmaceuticals reports Q3 net loss of $1.8 million
Adial Pharmaceuticals Q3 Net Income USD -1.8 Million
THOMSON REUTERS  ·  11-14
Adial Pharmaceuticals Q3 Net Income USD -1.8 Million
Adial Pharmaceuticals: Implementing FDA's Recommendations Based on Eop2 Meeting, to Advance Ad04 Toward Phase 3 Development
THOMSON REUTERS  ·  11-14
Adial Pharmaceuticals: Implementing FDA's Recommendations Based on Eop2 Meeting, to Advance Ad04 Toward Phase 3 Development
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  11-14
Calendar of U.S. Earnings Expected in the Week Ahead
Adial Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Reuters  ·  11-07
Adial Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
GlobeNewswire  ·  10-17
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Strategic Advancements and Genetic Testing Propel Adial Pharmaceuticals to a Buy Rating
TIPRANKS  ·  10-11
Strategic Advancements and Genetic Testing Propel Adial Pharmaceuticals to a Buy Rating
Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing
TIPRANKS  ·  10-09
Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing
Adial Pharmaceuticals Raised to Buy From Hold by Maxim Group
Dow Jones  ·  09-30
Adial Pharmaceuticals Raised to Buy From Hold by Maxim Group
Adial Pharmaceuticals Inc : Maxim Group Raises to Buy From Hold
THOMSON REUTERS  ·  09-30
Adial Pharmaceuticals Inc : Maxim Group Raises to Buy From Hold
Adial Pharmaceuticals upgraded to Buy from Hold at Maxim
TIPRANKS  ·  09-30
Adial Pharmaceuticals upgraded to Buy from Hold at Maxim
Adial Pharmaceuticals Advances AD04 with FDA Support
TIPRANKS  ·  09-16
Adial Pharmaceuticals Advances AD04 with FDA Support
Adial Pharmaceuticals Provides Business Update Following Favorable Comments From FDA End-of-Phase 2 (Eop2) Meeting for Ad04
THOMSON REUTERS  ·  09-16
Adial Pharmaceuticals Provides Business Update Following Favorable Comments From FDA End-of-Phase 2 (Eop2) Meeting for Ad04
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
GlobeNewswire  ·  09-16
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
GlobeNewswire  ·  09-03
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments
GlobeNewswire  ·  08-20
Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments

Introduction

Company Name.
Adial Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Issue price:
--